Free Trial

Acorda Therapeutics (ACORQ) Stock Price, News & Analysis

+0.09 (+14.75%)
(As of 05/20/2024 ET)
Today's Range
50-Day Range
52-Week Range
16,122 shs
Average Volume
26,220 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target

About Acorda Therapeutics

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

ACORQ Stock Price History

ACORQ Stock News Headlines

No headlines for this company have been tracked by
Receive ACORQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$117.63 million
Cash Flow
$35.00 per share
Book Value
($127.17) per share


Free Float
Market Cap
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Ron Cohen M.D. (Age 68)
    Founder, CEO, President & Director
    Comp: $897.4k
  • Mr. Michael A. Gesser M.B.A. (Age 61)
    CFO & Treasurer
    Comp: $611.55k
  • Mr. Neil S. Belloff Esq. (Age 64)
    General Counsel & Corporate Secretary
    Comp: $616.27k
  • Ms. Denise J. Duca
    Executive Vice President of Human Resources
  • Mr. Kerry M. Clem (Age 54)
    Chief Commercial Officer
    Comp: $592.23k
  • Sofia Ali
    Senior VP of Operations & Strategic Planning
  • Susan Way
    Senior VP of Drug Development & Regulatory Affairs
  • Dr. Wise Young M.D. (Age 74)
    Ph.D., Special Scientific Advisor
    Comp: $10k

ACORQ Stock Analysis - Frequently Asked Questions

How have ACORQ shares performed in 2024?

Acorda Therapeutics' stock was trading at $0.44 at the beginning of 2024. Since then, ACORQ stock has increased by 59.1% and is now trading at $0.70.
View the best growth stocks for 2024 here

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACORQ) issued its earnings results on Monday, April, 1st. The company reported ($175.32) earnings per share for the quarter. The firm earned $37.99 million during the quarter. Acorda Therapeutics had a negative net margin of 227.75% and a negative trailing twelve-month return on equity of 2,206.93%.

How do I buy shares of Acorda Therapeutics?

Shares of ACORQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACORQ) was last updated on 5/21/2024 by Staff

From Our Partners